聚乙二醇干扰素α-2a治疗慢性乙型肝炎的抗病毒、抗纤维化疗效观察

Anti-viral and Anti-fibrotic Efficacy of Pegylated Interferon α-2a in the Treatment of Patients with Chronic Hepatitis B

目的:观察聚乙二醇干扰素α-2a治疗慢性乙型肝炎的抗病毒、抗纤维化疗效。方法:100例HBe Ag阳性的慢性乙肝患者,给予聚乙二醇干扰素α-2a 180μg,皮下注射,每周1次,疗程48周。观察其治疗12周、24周、48周时血清HBs Ag定量、HBe Ag定量、ALT复常率、HBV-DNA阴转率、瞬时肝弹性测定数值。结果:患者在治疗12周、24周、48周时血清HBs Ag定量、HBe Ag定量逐渐下降,HBV-DNA阴转率增加,ALT复常率提高,瞬时肝弹性测定数值逐渐下降,各治疗节点间比较,差异均有统计学意义(P<0.05);且HBs Ag定量、HBe Ag定量与瞬时肝弹性测定之间呈正相关,相关系数分别为0.826、0.782(P<0.05)。结论:聚乙二醇干扰素α-2a在慢性乙肝患者的抗病毒、抗纤维化治疗中,疗效确定。

Objective： To observe the anti-viral and anti-fibrotic effect of pegylated interferon ct-2a in the treatment of chronic hep- atitis B patients. Methods： Totally 100 eases of HBeAg-positive chronic hepatitis B patients were treated with 180μg pegylated inter- feron α-2a with subcutaneous injection, once a week for 48 weeks. In the 12th, 24th and 48th week, the serum HBsAg quantification, HBeAg quantification, ALT normalization rate, HBV-DNA negative rate and transient liver elasticity were measured. Results： In the 12th, 24th and 48th week, the HBeAg quantification was gradually decreased, the HBV-DNA negative rate and ALT normalization rate were both increased, and the transient liver elasticity was decreased. The differences among the time nodes were statistically significant （ P 〈 0.05 ）. Moreover, the correlation coefficient between the HBsAg or HBeAg positive quantification and the transient liver elasticity quantification was 0.826 and 0.782, respectively （ P 〈 0.05 ）. Conclusion： Pegylated interferon α-2a has notable anti-viral and anti- fibr^ic efficacy in the treatment of patients with chronic hepatitis B.